A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT ID: NCT00782340

Last Updated: 2014-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 263 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2010-09-30

Brief Summary

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Detailed Description

Systolic blood pressure is transiently and minimally decreased in healthy individuals upon standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness and blurred or impaired vision, among other symptoms.

The autonomic nervous system has a central role in the regulation of blood pressure. Primary Autonomic Failure is manifested in a variety of syndromes. Orthostatic hypotension is a usual presenting symptom. Primary Autonomic Failure may be the primary diagnosis, and classifications include pure autonomic failure (PAF), also called idiopathic orthostatic hypotension (Bradbury-Eggleston syndrome) autonomic failure with multiple system atrophy (Shy-Drager syndrome) and also Parkinson's disease. Regardless of the primary condition, autonomic dysfunction underlies orthostatic hypotension.

Orthostatic hypotension may be a severely disabling condition which can seriously interfere with the quality of life of afflicted subjects. Currently available therapeutic options provide some symptomatic relief in a subset of subjects, but are relatively ineffective and are often accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone, methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the pharmacological interventions that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of these currently available therapeutic options, and the incapacitating nature and often progressive downhill course of disease, point to the need for an improved therapeutic alternative.

The current withdrawal design study will measure the efficacy of droxidopa on symptoms of neurogenic orthostatic hypotension in patients randomized to continued droxidopa treatment versus placebo, following 14 days of double-blind treatment.

droxidopa

droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.

Conditions

Symptomatic Neurogenic Orthostatic Hypotension (NOH); Non-diabetic Neuropathy; Primary Autonomic Failure; Dopamine Beta Hydroxylase Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Droxidopa

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Group Type: ACTIVE_COMPARATOR

Droxidopa

Intervention Type: DRUG

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Placebo

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Interventions

Placebo

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Intervention Type: DRUG

Droxidopa

100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

To be eligible for inclusion, each patient must fulfill the following criteria:

• Male or female and aged 18 years or over
• Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies
• A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;
• Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.

Exclusion Criteria

• Currently taking ephedrine or midodrine
• Patients taking ephedrine or midodrine must stop taking these drugs at least 2 days prior to their baseline visit (Visit 2).
• The use of short-acting anti-hypertensive medications at bedtime is permitted.
• Currently taking tri-cyclic antidepressant medication or other norepinephrine re-uptake inhibitors;
• Have changed dose, frequency and or type of prescribed medication, within two weeks of study start (excluding ephedrine and midodrine)
• History of more than moderate alcohol consumption
• History of known or suspected drug or substance abuse
• Women of childbearing potential who are not using a medically accepted contraception
• For WOCP a serum beta HCG pregnancy test must be conducted at screening, and a urine pregnancy test must be conducted at baseline and study termination; the results must be negative at screening and at baseline for the patient to receive study medication.
• Sexually active males whose partner is a WOCP and who do not agree to use condoms for the duration of the study and for 30 days after the last dose;
• Women who are pregnant or breast feeding
• Known or suspected hypersensitivity to the study medication or any of its ingredients
• Pre-existing sustained severe hypertension (BP 180/110 mmHg in the sitting position)
• Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia
• Any other significant systemic, hepatic, cardiac or renal illness
• Diabetes mellitus or insipidus
• Have a history of closed angle glaucoma
• Have a known or suspected malignancy
• Have a serum creatinine level > 130 mmol/L
• Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug
• In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing
• In the investigator's opinion, are unable to adequately co-operate because of individual or family situation
• In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia
• Are not able or willing to comply with the study requirements for the duration of the study
• Have participated in another clinical trial with an investigational agent (including named patient or compassionate use protocol) within 4 weeks before the start of the study
• Previous enrolment in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chiltern International Inc.

INDUSTRY

Sponsor Role: collaborator

Chelsea Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stephen Greer, MD

Role: PRINCIPAL_INVESTIGATOR

Arkansas Cardiology

Alberto Vasquez, MD

Role: PRINCIPAL_INVESTIGATOR

Suncoast Neuroscience

Richard Hull, MD

Role: PRINCIPAL_INVESTIGATOR

North Alabama Neuroscience

Brent Goodman, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Alvin McElveen, MD

Role: PRINCIPAL_INVESTIGATOR

Bradenton Neurology, Inc

Mazen Dimachkie, MD

Role: PRINCIPAL_INVESTIGATOR

University of Kansas Medical Center

Locations

North Alabama Neuroscience

Huntsville, Alabama, United States

Mayo Clinic-Arizona

Scottsdale, Arizona, United States

Arkansas Cardiology

Little Rock, Arkansas, United States

University of California, Irvine

Irvine, California, United States

Bradenton Neurology, Inc

Bradenton, Florida, United States

Suncoast Neuroscience Associates, Inc

St. Petersburg, Florida, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Cncs, Ninds,Nih

Bethesda, Maryland, United States

Nerological Reserch Center at Hattiesburg

Hattiesburg, Mississippi, United States

North Shore Hospital

Manshasette, New York, United States

Pennsylvania Hospital of the University of PA Health System- Department of Neurology

Philadelphia, Pennsylvania, United States

HAN Neurological Associates

Upland, Pennsylvania, United States

Baylor College of Medicine

Houston, Texas, United States

Evergreen Hospital Medical Center; Booth Gardner Parkinson's Care Center

Kirkland, Washington, United States

University of Calgary

Calgary, Alberta, Canada

University of Alberta

Edmonton, Alberta, Canada

Movment Disorder Clinic Deer lodge Centre

Winnipeg, Manitoba, Canada

David B. King, - Private Clinic

Halifax, Nova Scotia, Canada

London Health Sciences Centre, UH

London, Ontario, Canada

UHNresearch

Toronto, Ontario, Canada

IRCM

Montreal, Quebec, Canada

Countries

United States; Canada

References

Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017 May 12;17(1):90. doi: 10.1186/s12883-017-0867-5.

Reference Type: DERIVED

PMID: 28494751 (View on PubMed)

Francois C, Rowse GJ, Hewitt LA, Vo P, Hauser RA. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. BMC Neurol. 2016 Aug 18;16(1):143. doi: 10.1186/s12883-016-0665-5.

Reference Type: DERIVED

PMID: 27538531 (View on PubMed)

Other Identifiers

Droxidopa NOH301

Identifier Type: -

Identifier Source: org_study_id

NCT00879567

Identifier Type: -

Identifier Source: nct_alias